Evaluating the Efficacy and Perception of HS Treatment Options

Image Credit: © LASZLO - stock.adobe.com

Managing hidradenitis suppurativa (HS) effectively remains challenging for dermatology clinicians, necessitating innovative and effective treatment options. Recently, Spherix Global Insights took a deep dive into secukinumab (Cosentyx; Novartis) versus adalimumab (Humira; AbbVie) in HS treatment performance.¹

Awareness and Usage of Secukinumab

According to the recent data from Spherix Global Insights, secukinumab has seen a steady rise in awareness among US dermatologists surveyed (n = 76). Surveyed dermatologists have been practicing for at least 2 years and have experience in managing HS in adult patients and were part of quantitative research (n = 76) and a few of those participated in qualitative research (n = 8). Out of those, 59 are actively prescribing secukinumab. This increased awareness is critical as it translates into a higher likelihood of the drug being considered in treatment plans for HS patients.

The data also highlights that dermatologists have started using secukinumab more frequently, with its usage increasing steadily since its launch. This trend is a positive indicator of the drug’s acceptance in clinical practice, driven by the continuous efforts in promoting and educating healthcare professionals about its benefits.

Comparative Performance

Efficacy and Safety

When comparing secukinumab to adalimumab, the study provides a detailed evaluation based on several performance metrics. The data collected in May 2024 indicates that secukinumab is perceived to have superior efficacy in several critical areas. Specifically, 56% of the respondents believe that secukinumab performs better than adalimumab in terms of overall efficacy. Additionally, 61% of users rated secukinumab higher in overall safety, which is a significant consideration in long-term treatment plans for chronic conditions like HS.

Patient Quality of Life

Improving patient quality of life (QoL) is a primary goal in treating HS. According to the survey, 56% of the users perceived that secukinumab had a better impact on patient QoL compared to adalimumab. This is crucial as HS significantly affects patients' physical and psychological well-being, and a treatment that offers noticeable improvements in QoL can be a game-changer.

Symptom Management

In managing specific HS symptoms, dermatologists report secukinumab shows promising results. For instance, 51% of the respondents perceive secukinumab is more effective in reducing flares compared to adalimumab. Similarly, it was found to be more effective in decreasing the total abscess and inflammatory nodule (AN) count, with 51% of users favoring secukinumab over adalimumab. This ability to manage and reduce the severity of symptoms makes secukinumab a valuable option for HS patients.

Market Dynamics and Future Prospects

The deep dive into secukinumab’s market dynamics provides insights into its current standing and future potential. The data indicates that secukinumab has a strong foothold, with positive perceptions from dermatologists regarding its clinical benefits. However, challenges remain, particularly in terms of out-of-pocket costs and ease of access, where adalimumab still holds a slight edge. Specifically, 54% of the respondents felt that Humira had better ease of access, while 30% believed secukinumab had higher out-of-pocket costs.

Despite these challenges, the sustained efficacy and overall performance of secukinumab continue to garner positive responses. As dermatology clinicians become more familiar with its benefits and as ongoing promotions and educational initiatives continue, it is likely that secukinumab will see increased adoption and use.

Conclusion

Spherix Global Insights shared with Dermatology Times that their team will continue to track these trends through May 2025. Secukinumab’s journey in the HS treatment landscape since its October 2023 approval² showcases a promising trajectory, driven by its efficacy, safety, and positive impact on patient quality of life. While the survey shows it faces competition from established treatments like adalimumab, its growing acceptance among dermatologists and favorable performance metrics indicate a strong future.

References

1) Launch Dynamix: Cosentyx in HS Deep Dive wave 2 (US). Spherix Global Insights. May 2024. Accessed July 16, 2024.

2) Buchanan L. FDA approves secukinumab for Hidradenitis Suppurativa. Dermatology Times. October 31, 2023. Accessed July 16, 2024. https://www.dermatologytimes.com/view/fda-approves-secukinumab-for-hidradenitis-suppurativa